These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16491742)

  • 1. [Workshop II--Clinical and therapeutic pathways].
    Ital Heart J; 2005 Nov; 6 Suppl 6():12S-26S. PubMed ID: 16491742
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
    De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M
    J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158
    [No Abstract]   [Full Text] [Related]  

  • 3. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
    Hassan AK; Liem SS; van der Kley F; Bergheanu SC; Wolterbeek R; Bosch J; Bootsma M; Zeppenfeld K; van der Laarse A; Atsma DE; Jukema JW; Schalij MJ
    Catheter Cardiovasc Interv; 2009 Aug; 74(2):335-43. PubMed ID: 19642182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary percutaneous coronary intervention decision-making becomes more confusing: where do glycoprotein 2b/3a inhibitors "fit" now?
    Morrison DA
    Catheter Cardiovasc Interv; 2009 Aug; 74(2):344-7. PubMed ID: 19642178
    [No Abstract]   [Full Text] [Related]  

  • 5. [The FATA study].
    Merlini PA; Valgimigli M
    G Ital Cardiol (Rome); 2009 Jun; 10(6):358-63. PubMed ID: 19603606
    [No Abstract]   [Full Text] [Related]  

  • 6. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study.
    Campo G; Valgimigli M; Gemmati D; Percoco G; Tognazzo S; Cicchitelli G; Catozzi L; Malagutti P; Anselmi M; Vassanelli C; Scapoli G; Ferrari R
    J Am Coll Cardiol; 2006 Dec; 48(11):2178-85. PubMed ID: 17161242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of acute ST-segment elevation myocardial infarction. I. Reperfusion therapy.
    Glancy DL; Breaux DM; Subramaniam PN; Pappas ND
    J La State Med Soc; 2002; 154(4):183-90; quiz 190. PubMed ID: 12236401
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention.
    Huang R; Sacks J; Thai H; Goldman S; Morrison DA; Barbiere C; Ohm J
    Catheter Cardiovasc Interv; 2005 May; 65(1):25-33. PubMed ID: 15800889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of therapeutic trends in myocardial infarction.
    Milasinovic D; Teischinger L; Luerzer G; Mohl W
    Wien Klin Wochenschr; 2007; 119(11-12 Suppl 1):15-9. PubMed ID: 19618592
    [No Abstract]   [Full Text] [Related]  

  • 10. Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction.
    Exaire JE; Fathi RB; Brener SJ; Karha J; Ellis SG; Bhatt DL
    Arch Cardiol Mex; 2006; 76(4):376-82. PubMed ID: 17315613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study.
    Tousek P; Rokyta R; Tesarova J; Pudil R; Belohlavek J; Stasek J; Rohac F; Widimsky P
    Acute Card Care; 2011 Sep; 13(3):116-22. PubMed ID: 21526919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The FINESSE trial].
    Petronio AS; Piscione F
    G Ital Cardiol (Rome); 2009 Jan; 10(1):1-5. PubMed ID: 19292014
    [No Abstract]   [Full Text] [Related]  

  • 13. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shimada YJ; Nakra NC; Fox JT; Kanei Y
    Am J Cardiol; 2012 Mar; 109(5):624-8. PubMed ID: 22152971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
    de Queiroz Fernandes Araújo JO; Veloso HH; Braga De Paiva JM; Filho MW; Vincenzo De Paola AA
    Am Heart J; 2004 Dec; 148(6):937-43. PubMed ID: 15632875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distal embolization during angioplasty for acute myocardial infarction: is pharmacological protection enough?
    De Carlo M; Limbruno U; Pistolesi S; Fontanini G; Petronio AS; Balbarini A; De Caterina R
    Thromb Haemost; 2005 Sep; 94(3):680-1. PubMed ID: 16268491
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
    De Servi S; Mariani M; Vandoni P; Dellavalle A; Politi A; Poletti F; Bonizzoni E; Leoncinie M;
    J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):159-65. PubMed ID: 16645379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
    Mesquita A; Baptista J; Palos J; Seabra-Gomes R
    J Invasive Cardiol; 1999 Jun; 11(6):379-82. PubMed ID: 10745556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
    Kandzari DE; Hasselblad V; Tcheng JE; Stone GW; Califf RM; Kastrati A; Neumann FJ; Brener SJ; Montalescot G; Kong DF; Harrington RA
    Am Heart J; 2004 Mar; 147(3):457-62. PubMed ID: 14999194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of c7E3 Fab in conjunction with primary coronary stenting for acute myocardial infarctions complicated by cardiogenic shock.
    Schultz RD; Heuser RR; Hatler C; Frey D
    Cathet Cardiovasc Diagn; 1996 Oct; 39(2):143-8. PubMed ID: 8922314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.